Sinus Disease in Young Children With Cystic Fibrosis

Recruiting Observational Study
Cystic Fibrosis in Children Cystic Fibrosis Chronic Rhinosinusitis (Diagnosis) Olfactory Disorder Olfactory Impairment
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
2 – 8
Sex
Any
Study type
Observational
Participants needed
80 (estimated)
Sponsor
University of California, Los Angeles · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This is a prospective, observational study examining the impact of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators on chronic rhinosinusitis (CRS) and olfactory dysfunction (OD) in young children with cystic fibrosis (YCwCF). This study involves two groups: children 2-8 years old, inclusive at initial visit, receiving highly effective modulator therapy (HEMT)…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: HEMT Group: * Children with documentation of a CF diagnosis * Age 2-8 years old at first study visit * CFTR mutation consistent with FDA labeled indication of highly effective modulator therapy (ivacaftor or elexacaftor/tezacaftor/ivacaftor) * Clinician intent to prescribe ivac…
Contacts

Daniel M Beswick, MD

310-206-8457

dbeswick@mednet.ucla.edu

CONTACT

Marlene Florian

424-946-5862

mflorian@mednet.ucla.edu

CONTACT